{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T04:33:40Z","timestamp":1769920420968,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Treating chordoma through surgery alone is often ineffective. Thus, surgery often performed with irradiation, with a reported 5-year survival rate of 60\u201375%. The clinical course varies, and disease rarity prevents larger number of clinical investigations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 19 patients with clival chordomas were retrospectively extracted from our institutional database. They were initially treated with maximal tumor removal using the extended transsphenoidal approach between March 2006 and January 2021. When total tumor removal was achieved, prophylactic irradiation was not performed. If tumor remnants or recurrence were confirmed, Gamma Knife (GK) radiosurgery was performed. The mean follow-up period was 106.7\u2009months (ranged 27\u2013224\u2009months). The clinical course and prognostic factors were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Total removal was achieved in 10 patients, whereas 4 patients suffered recurrence and required GK. GK was applied to 11 patients with a 50% isodose of 13\u201318\u2009Gy (mean: 15.4\u2009Gy), and eight patients remained progression free, whereas three patients suffered repeated local recurrence and died of tumor-related complications. The mean overall progression-free interval was 57.2\u2009months (range: 6\u2013169\u2009months). One male patient died of tumor un-related lung cancer 36\u2009months after the initial treatment, and other patients survived throughout the observational periods. The mean overall survival was 106.7\u2009months (range: 27\u2013224\u2009months). Thus, the 5-year survival rate was 94.7%. Statistical analysis indicated that sex (men), &gt;\u200915\u2009Gy of 50% isodose by GK, and screening brain examinations as prophylactic medicine were significant favorable prognostic factors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The favorable outcomes in this investigation suggest the importance of early detection and treatment. Surgery may enable better conditions for sufficient GK doses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02234-4","type":"journal-article","created":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T07:02:40Z","timestamp":1621666960000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Midterm prognosis and surgical implication for clival chordomas after extended transsphenoidal tumor removal and gamma knife radiosurgery"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6834-6468","authenticated-orcid":false,"given":"Yoshikazu","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidefumi","family":"Jokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teiji","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,22]]},"reference":[{"issue":"3","key":"2234_CR1","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/1097-0142(19930201)71:3<735::AID-CNCR2820710314>3.0.CO;2-8","volume":"71","author":"J Bjornsson","year":"1993","unstructured":"Bjornsson J, Wold LE, Ebersold MJ, Laws ER. Chordoma of the mobile spine. A clinicopathologic analysis of 40 patients. Cancer. 1993;71(3):735\u201340. https:\/\/doi.org\/10.1002\/1097-0142(19930201)71:3<735::AID-CNCR2820710314>3.0.CO;2-8.","journal-title":"Cancer"},{"issue":"4","key":"2234_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/CCO.0b013e3281214448","volume":"19","author":"PG Casali","year":"2007","unstructured":"Casali PG, Stacchiotti S, Sangalli C, Olmi P, Gronchi A. Chordoma. Curr Opin Oncol. 2007;19(4):367\u201370. https:\/\/doi.org\/10.1097\/CCO.0b013e3281214448.","journal-title":"Curr Opin Oncol"},{"key":"2234_CR3","doi-asserted-by":"publisher","unstructured":"Chauvel KA, Taillat F, Gille O, Rivel J, Vital JM, Bioulac-Sage P, et al. Giant vertebral notochordal rest: a new entity distinct from chordoma. Histopathology. 2005;47(6):646\u20136. https:\/\/doi.org\/10.1111\/j.1365-2559.2005.02168.x.","DOI":"10.1111\/j.1365-2559.2005.02168.x"},{"key":"2234_CR4","doi-asserted-by":"publisher","unstructured":"Chen K, Mo J, Zhou M, Wang G, Wu G, Chen H, et al. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol. 2014;31(4):886. https:\/\/doi.org\/10.1007\/s12032-014-0886-7.","DOI":"10.1007\/s12032-014-0886-7"},{"key":"2234_CR5","doi-asserted-by":"publisher","unstructured":"Ferraresi V, Nuzzo C, Zoccali C, Marandino F, Vidiri A, Salducca N, et al. Chordoma: clinical charateristics, management and prognosis of a case series of 25 patients. BMC Cancer. 2010;10(1):22. https:\/\/doi.org\/10.1186\/1471-2407-10-22.","DOI":"10.1186\/1471-2407-10-22"},{"key":"2234_CR6","doi-asserted-by":"publisher","unstructured":"Guan X, Gao J, Hu J, Hu W, Yang J, Qiu X, et al. The preliminary results of proton and carbon ion therapy for chordoma and chondrosarcoma of the skull base and cervical spine. Radiat Oncol. 2019;14(1):206. https:\/\/doi.org\/10.1186\/s13014-019-1407-9.","DOI":"10.1186\/s13014-019-1407-9"},{"key":"2234_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.clineuro.2019.01.017","volume":"178","author":"RFA Hafez","year":"2019","unstructured":"Hafez RFA, Fahmy OM, Hassan HT. Gamma knife surgery efficacy in controling postoperative residual chordoma growth. Clin Neurol Neurosurg. 2019;178:51\u20135. https:\/\/doi.org\/10.1016\/j.clineuro.2019.01.017.","journal-title":"Clin Neurol Neurosurg"},{"key":"2234_CR8","doi-asserted-by":"publisher","unstructured":"Hulou MM, Garcia CR, Slone SA, Dugan A, Lei F, Huang B, et al. Comprehensive review of cranial chordomas using national database in the USA. Clin Oncol R Coll Radiol. 2019;31(9):e149\u201359. https:\/\/doi.org\/10.1016\/j.clon.2019.06.004.","DOI":"10.1016\/j.clon.2019.06.004"},{"issue":"10","key":"2234_CR9","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00701-017-3163-7","volume":"159","author":"M Jagerberg","year":"2017","unstructured":"Jagerberg M, ElRahal A, Dammann P, Merkler D, Weber DC, Schaller K. Clival chordoma: a single-center outcome analysis. Acta Neurochir. 2017;159(10):1815\u201323. https:\/\/doi.org\/10.1007\/s00701-017-3163-7.","journal-title":"Acta Neurochir"},{"issue":"4","key":"2234_CR10","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3109\/02688697.2010.546896","volume":"25","author":"BJ Jian","year":"2011","unstructured":"Jian BJ, Bloch OG, Yang I, Han SJ, Aranda D, Parsa AT. A comprehensive analysis of intracranial chordoma and survival: a systemic review. Br J Neurosurg. 2011;25(4):446\u201353. https:\/\/doi.org\/10.3109\/02688697.2010.546896.","journal-title":"Br J Neurosurg"},{"key":"2234_CR11","first-page":"88","volume":"21","author":"JH Kim","year":"2014","unstructured":"Kim JH, Jung HH, Chang JH, Chang JW, Park YG, Chang WS. Gamma knife surgery for intracranial chordoma and chondrosarcoma: radiosurgical perspectives and treatment outcomes. J Neurosurg. 2014;21:88\u201397.","journal-title":"J Neurosurg"},{"key":"2234_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.jocn.2018.04.008","volume":"53","author":"P Leah","year":"2018","unstructured":"Leah P, Dower A, Vescovi C, Mulcahy M, Al KD. Clinical experience of intracranial chordoma \u2013 a systematic review and meta-analysis of the literature. J Clin Neurosci. 2018;53:6\u201312. https:\/\/doi.org\/10.1016\/j.jocn.2018.04.008.","journal-title":"J Clin Neurosci"},{"issue":"6","key":"2234_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1179\/174313208X297878","volume":"30","author":"AL Liu","year":"2008","unstructured":"Liu AL, Wang ZC, Sun SB, Wang MH, Luo B, Liu P. Gamma knife radiosurgery for residual skull base chordomas. Neurol Res. 2008;30(6):557\u201361. https:\/\/doi.org\/10.1179\/174313208X297878.","journal-title":"Neurol Res"},{"key":"2234_CR14","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1016\/j.wneu.2018.02.127","volume":"115","author":"O Sanusi","year":"2018","unstructured":"Sanusi O, Arnaout O, Rahme RJ, Horbinski C, Chandler JP. Surgical resection and adjuvant radiation therapy in the treatment of skull base chordomas. World Neurosurg. 2018;115:e115\u201321.","journal-title":"World Neurosurg"},{"key":"2234_CR15","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1002\/cncr.28032","volume":"1119","author":"NR Smoll","year":"2013","unstructured":"Smoll NR, Gautschi OP, Radovanovi I, Schaller K, Weber DC. Incidence and relative survival of chordomas: the standardized mortality ratio and the impact of chordomas on a population. Cancer. 2013;1119:2029\u201337.","journal-title":"Cancer"},{"issue":"4","key":"2234_CR16","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s12178-015-9311-x","volume":"8","author":"X Sun","year":"2015","unstructured":"Sun X, Hornicek F, Schwab JH. Chordooma: an update on the pathophysiology and molecular mechanisms. Curr Rev Musculoskelet Med. 2015;8(4):344\u201352. https:\/\/doi.org\/10.1007\/s12178-015-9311-x.","journal-title":"Curr Rev Musculoskelet Med"},{"issue":"1","key":"2234_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13014-018-1173-0","volume":"13","author":"M Takagi","year":"2018","unstructured":"Takagi M, Demizu Y, Nagano F, Terashima K, Fujii O, Jin D, et al. Treatment outcomes of proton or carbon ion therapy for skull base chordoma: a retrospective study. Radiat Oncol. 2018;13(1):232. https:\/\/doi.org\/10.1186\/s13014-018-1173-0.","journal-title":"Radiat Oncol"},{"key":"2234_CR18","doi-asserted-by":"publisher","unstructured":"Tsutsumi S, Akiba C, Suzuki T, Nakanishi H, Izumi H, Yasumoto Y, et al. Skull base chondroid chordoma: atypical case manifesting as intratumoral hemorrhage and literature review. Clin Neuroradiol. 2014;24(4):313\u201320. https:\/\/doi.org\/10.1007\/s00062-014-0321-7.","DOI":"10.1007\/s00062-014-0321-7"},{"issue":"2","key":"2234_CR19","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1016\/S1470-2045(11)70337-0","volume":"13","author":"BP Walcott","year":"2012","unstructured":"Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, Ferreira MJ. Chordoma: current concepts, management, and future directions. Lancet Oncol. 2012;13(2):e69\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(11)70337-0.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2234_CR20","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/path.1711660402","volume":"166","author":"D Wynfold-Tomas","year":"1992","unstructured":"Wynfold-Tomas D. P53 in tumour pathology: can we trust immunohistochemistry? J Pathol. 1992;166(4):329\u201330. https:\/\/doi.org\/10.1002\/path.1711660402.","journal-title":"J Pathol"},{"key":"2234_CR21","doi-asserted-by":"publisher","unstructured":"Yakkioui Y, Temel Y, Creytens D, Jahanshahi A, Fleischeuer R, Santegoeds RG, et al. A comparison of cell-cycle markers in skull base and sacral chordomas. World Neurosurg. 2014;82(1-2):e311\u20138. https:\/\/doi.org\/10.1016\/j.wneu.2013.01.131.","DOI":"10.1016\/j.wneu.2013.01.131"},{"key":"2234_CR22","first-page":"655","volume":"2014","author":"Y Yakkioui","year":"1846","unstructured":"Yakkioui Y, van Overbeeke JJ, Santegoeds R, van Engeland M, Temei Y. Chordoma: the entity. Biochim Biophys Acta. 1846;2014:655\u201369.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"2234_CR23","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4103\/ajns.AJNS_61_17","volume":"13","author":"WK Zakaria","year":"2018","unstructured":"Zakaria WK, HafezRF TAN. Gamma knife management of skull base chordomas: is it a choice? Asian J Neurosurg. 2018;13(4):1037\u201341. https:\/\/doi.org\/10.4103\/ajns.AJNS_61_17.","journal-title":"Asian J Neurosurg"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02234-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02234-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T07:02:59Z","timestamp":1621666979000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02234-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,22]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02234-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,22]]},"assertion":[{"value":"8 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The surgical policy was explained preoperatively to the patients and written informed consent was obtained, and the study design was approved by the internal ethics committee of Kohnan Hospital 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}